300511 Shanghai Xuerong Bio-Technology
- 4.79
- +0.80+20.05%
Shanghai Xuerong Bio-Technology News
The China Securities Convertible Index rose 0.03% at the beginning of the market. Xuerong Convertible Bonds rose more than 16%, Dongbao Convertible Bonds rose more than 8%, and Titan Convertible Bonds rose more than 5%.
The China Securities Convertible Index rose 0.03% at the beginning of the market. Xuerong Convertible Bonds rose more than 16%, Dongbao Convertible Bonds rose more than 8%, and Titan Convertible Bonds rose more than 5%.
The synthetic biology concept strengthened once again. Blue Bio was strong for 8 consecutive boards, Xuerong Biotech went up and down 20CM, and Golden Ham and Xinhecheng followed suit.
The synthetic biology concept strengthened once again. Blue Bio was strong for 8 consecutive boards, Xuerong Biotech went up and down 20CM, and Golden Ham and Xinhecheng followed suit.
Artificial meat concept stocks opened sharply, Xuerong Biotech and Shuangta Foods rose and stopped, and Sihuan Biotech, Jiahua, Dongbao Biotech, and Suobao Protein strengthened one after another.
Artificial meat concept stocks opened sharply, Xuerong Biotech and Shuangta Foods rose and stopped, and Sihuan Biotech, Jiahua, Dongbao Biotech, and Suobao Protein strengthened one after another.
The A-share artificial meat sector boosted and stopped Shuangta Foods
Gelonghui, May 10 | Xuerong Biotech rose more than 14%, Shuangta Food closed, and Dongbao Biotech, Suobao Protein, Zuming Co., Ltd., and Chengzhi Co., Ltd. followed suit.
Xuerong Biotech (300511.SZ) reported first-quarter results, net profit of 5.2403 million yuan, a year-on-year decrease of 97.65%
Xuerong Biotech (300511.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Xuerong Biotech (300511.SZ) holds 1.96% shareholder Zhu Huancheng plans to liquidate and reduce holdings
Xuerong Biotech (300511.SZ) announced that Zhu Huancheng, the company's specific shareholder, plans to reduce its holdings by no more than 9.7711 million shares of the company through bulk transactions, centralized bidding, etc. within three months after the date of publication of this announcement (that is, no more than 1.96% of the company's total share capital, that is, no more than 100% of the company's shares held).
Express News | Xuerong Biology: The company's edible fungus products are generally sold around production bases and surrounding areas
Xuerong Biotech (300511.SZ): Plans to use capital raising related claims to increase capital for wholly-owned subsidiaries
Gelonghui, Feb. 23, 丨 Xuerong Biotech (300511.SZ) announced that the company increased its capital at RMB 1 yuan/share through debt-for-share swaps of 170 million yuan in part of the debt raised against its wholly-owned subsidiary Guangxi Xuerong Biotechnology Co., Ltd. (“Guangxi Xuerong”). After the capital increase is completed, the registered capital of Guangxi Xuerong will increase from 10 million yuan to 270 million yuan, and it is still a wholly-owned subsidiary of the company.
Xuerong Biotech (300511.SZ) and related personnel accepted the Shanghai Securities Regulatory Bureau's administrative supervision measures decision
Xuerong Biotech (300511.SZ) issued an announcement. The company received the Shanghai Securities Regulatory Bureau on December 25, 2023...
Xuerong Biotech (300511.SZ): Net loss of 169 million yuan in the third quarter
On October 27, Gelonghui Biotech (300511.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 569 million yuan, a year-on-year decrease of 15.86%; net profit attributable to shareholders of listed companies was -169 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -172 million yuan; and basic earnings per share was -0.34 yuan.
Xuerong Biotech (300511.SZ): The controlling shareholder's concerted action has reduced its holdings by 0.67% at the end of Yinwan Huayi's holdings reduction of No. 1
GLONGHUI, August 14丨Xuerong Biotech (300511.SZ) announced that the company recently received a “Notice Concerning the Expiration of the Stock Holding Reduction Plan” issued by Yinwan Huayi No. 1, co-actor of Mr. Yang Yongping, the controlling shareholder of the company. As of August 13, 2023, the term of Yinwan Huayi No. 1's holdings reduction plan has expired. It reduced its holdings by a total of 3.3654 million shares, a change ratio of 0.67%.
Zhu Huancheng, a shareholder of Xuerong Biotech (300511.SZ), reduced his holdings by a total of 3.257 million shares at the end of the holdings reduction period
According to the Zhitong Finance App, Xuerong Biotech (300511.SZ) announced that the term of the company's shareholder Zhu Huancheng's holdings reduction plan has expired, reducing the company's holdings by a total of 3.257 million shares.
Company Q&A | Xuerong Biotech: Lintao Xuerong's recent project put into production is the Enoki mushroom project with a daily output of 65 tons
Gelonhui, May 29 丨 An investor asked Xuerong Biotech on an interactive platform: Recently, the company's Lintao production expansion project was fully put into operation. How much is Lintao's production capacity in Gansu? Xuerong Biotech responded: The project Lintao Xuerong recently put into production is the Enoki mushroom project with a daily output of 65 tons.
Company Q&A | Xuerong Biotech: Currently, the company's main market is the domestic market, and exports do not account for a high share
Gelonghui, May 29 丨 Some investors asked Xuerong Biotech on the interactive platform: Are the company's products exported? What is the approximate share of export revenue? Xuerong Biotech responded: Currently, the company's main market is the domestic market, and exports do not account for a high share.
Xuerong Biology (300511.SZ): Xuerongyuan (formerly Xuerong Pharmaceutical) launched products in the first quarter
Gelonhui, May 23丨An investor asked Xuerong Biotech (300511.SZ) on the investor interactive platform, “The company said it would invest 30 million dollars to establish Shanghai Xuerong Biomedical Co., Ltd. to develop functional foods and new drugs. What is the current situation and has it started operation?” Xuerong Biotech (300511.SZ) replied that Xuerongyuan (formerly Xuerong Pharmaceutical) launched products in the first quarter of 2023. You can learn more about the details through Douyin's “Xuerong Meal Flagship Store”.
Xuerong Biology (300511.SZ): Producing edible fungi using a factory method with stable supply every year without the use of pesticides
Glonghui, May 23 丨 An investor asked Xuerong Biotech (300511.SZ) on the investor interactive platform, “I would like to ask if the company added chemical fertilizers, growth regulators, preservatives, etc. in the production and processing of Enoki mushrooms, etc.” Xuerong Biotech (300511.SZ) replied that the company is a modern agricultural enterprise that produces edible fungi in a factory manner, with stable supply and no pesticides every year.
Xuerong Biology (300511.SZ): A fixed amount of credit is given to some large and high-quality customers
Gelonghui, May 16 丨 An investor asked Xuerong Biotech (300511.SZ) on the investor interactive platform, “Does the company have a long sales account for mushroom products? Do you mainly ship in cash? Or what was the cash flow situation in the first quarter, which was mainly credit sales? Is there a continuous cash inflow?” Xuerong Biotech replied that the company grants a certain amount of credit to some large and high-quality customers, and sells the rest using a pay-to-delivery model. For information such as cash flow for the first quarter, please check the company's report for the first quarter of 2023 disclosed on April 26, 2023.
Xuerong Biotech (300511.SZ): The controlling shareholder's concerted action Renbank Wanhuayi No. 1 reduced its shares by 0.67% after the holdings reduction period
Gelonghui, May 15, 丨 Xuerong Biotech (300511.SZ) announced that the company recently received a “Notice on the progress of the share holdings reduction plan” issued by the Company's controlling shareholder Yang Yongping, the company's controlling shareholder. As of May 14, 2023, Yinwan Huayi 1 had already halfway through its holdings reduction plan. It reduced its holdings by 3.3654 million shares, a change ratio of 0.67%.
Xuerong Biology (300511.SZ): The company sells Enoki mushroom and other products in Zibo
Gelonghui, May 10 丨 An investor asked Xuerong Biotech (300511.SZ) on the investor interactive platform, “The company's Dezhou factory is only 200 kilometers from Zibo City. Can you tell me if Enoki mushroom and other products are sold in Zibo City?” Xuerong Biotech replied that the company sells Enoki mushroom and other products in Zibo City.
Xuerong Biotech (300511.SZ): Will actively consolidate and develop the national market and strive to expand its share in the Southeast Asian market
Gelonghui, May 10 丨 An investor asked Xuerong Biotech (300511.SZ) on the investor interactive platform, “In recent years, trade volume between China and ASEAN has continued to buck the trend, and ASEAN has become a huge market source. Does the company deploy business personnel in Southeast Asian countries at the market expansion level? How big is it? Which countries are the main ones?” Xuerong Biotech replied that the company will actively consolidate and develop the national market and strive to expand its share in the Southeast Asian market.
Analysis
Price Target
No Data
